List of chemotherapy regimens: Difference between revisions
Jump to navigation
Jump to search
(→Overview: addition of regimen) |
|||
| Line 77: | Line 77: | ||
| Dexamethasone, cytarabine (high-dose ARA-C), cisplatin | | Dexamethasone, cytarabine (high-dose ARA-C), cisplatin | ||
| Recurrent or refractory [[non-Hodgkin lymphoma]] | | Recurrent or refractory [[non-Hodgkin lymphoma]] | ||
|- | |||
| '''DHAX-R''' <ref name="pmid20709662">{{cite journal |author=Lignon J, Sibon D, Madelaine I, ''et al.'' |title=Rituximab, Dexamethasone, Cytarabine, and Oxaliplatin (R-DHAX) Is an Effective and Safe Salvage Regimen in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma |journal=Clin Lymphoma Myeloma Leuk |volume=10 |issue=4 |pages=262–9 |year=2010 |month=August |pmid=20709662 |doi=10.3816/CLML.2010.n.055 |url=}}</ref> | |||
| Dexamethasone, cytarabine, oxaliplatin and rituximab | |||
| Relapsed or refractory B-cell [[non-Hodgkin lymphoma]] | |||
|- | |- | ||
| '''EC''' | | '''EC''' | ||
Revision as of 01:48, 21 August 2010
Associate Editor-in-Chief: Ross Bonander
Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
Acronyms often identify the individual agents used in combination chemotherapy regimens. Unfortunately, the letters used are not consistent across regimens, and in some cases (for example, "BEACOPP") the same letter is used to represent two different treatments. Because of this, there is not a naming standard for chemotherapy regimens, and this page merely represents commonly used conventions.
The term "Induction regimens" refers to a chemotherapy regimen which is used for the initial treatment of a disease.
| Name | Components | Example of uses, and other notes |
|---|---|---|
| ABVD [1] | Adriamycin, bleomycin, vinblastine, dacarbazine | Hodgkin's lymphoma |
| ABVE-PC [2] | Doxorubicin, bleomycin, vincristine, etoposide, prednisone, cyclophosphamide | Pediatric Hodgkin's lymphoma |
| AC | Adriamycin/Doxorubicin, Cyclophosphamide | Breast cancer |
| ADOC [3] | Doxorubicin, cisplatin, vincristine, cyclophosphamide | Thymic carcinoma |
| BEACOPP [4] | Bleomycin, etoposide, Adriamycin (doxorubicin), cyclophosphamide, Oncovin (vincristine), procarbazine, prednisone | Hodgkin's lymphoma |
| BEP | Bleomycin, etoposide, platinum (cisplatin) | Testicular cancer, germ cell tumors |
| CAF | Cyclophosphamide, Adriamycin/Doxorubicin, 5-FU/Fluorouracil | Breast cancer |
| CAV | Cyclophosphamide, Adriamycin/Doxorubicin, Vincristine | Lung cancer |
| CHOP | Cyclophosphamide, doxorubicin (hydroxydoxorubicin), vincristine (Oncovin), prednisone | Non-Hodgkin lymphoma |
| CHOP-R | CHOP + rituximab | B cell non-Hodgkin lymphoma |
| COP or CVP | Cyclophosphamide, vincristine (Oncovin), and prednisone | Non-Hodgkin lymphoma in patients with history of cardiovascular disease |
| CMF | Cyclophosphamide, Methotrexate, and 5-Fluorouracil | Breast Cancer |
| CODOX-M/IVAC [5] | Cyclophosphamide, vincristine, doxorubicin, methotrexate (CODOX-M) + ifosfamide, etopiside (VP-16), cytarabine (Ara-C) (IVAC) | Burkitt's lymphoma |
| COPP | Cyclophosphamide, Oncovin (vincristine), procarbazine and prednisone | Non-Hodgkin lymphoma |
| DA-EPOCH [6] | Dose-adjusted Etopiside, prednisone, vincristine (Oncovin), Cyclophosphamide and doxorubicin | Newly diagnosed, aggressive non-Hodgkin lymphoma |
| DHAP [7] | Dexamethasone, cytarabine (high-dose ARA-C), cisplatin | Recurrent or refractory non-Hodgkin lymphoma |
| DHAX-R [8] | Dexamethasone, cytarabine, oxaliplatin and rituximab | Relapsed or refractory B-cell non-Hodgkin lymphoma |
| EC | Epirubicin, Cyclophosphamide | Breast cancer |
| ECF | Epirubicin, cisplatin, fluorouracil | Gastric cancer and oesophageal cancer |
| ESHAP | Etopiside, methylprednisolone (Solu-medrol), cytarabine (ARA-C), cisplatin | Relapsed or refractory non-Hodgkin lymphoma |
| FN-D [9] | Fludarabine, mitoxantrone (Novantrone), dexamethasone | Recurrent or refractory indolent non-Hodgkin lymphoma |
| FOLFIRI [10] | Leucovorin, infusional fluorouracil, irinotecan | Metastatic colorectal cancer |
| FOLFOX | Fluorouracil, leucovorin (folinic acid), and oxaliplatin | Colorectal cancer |
| HYPER-CVAD [11] | Hyperfractionated cyclophosphamide, vincristine (Oncovin), doxorubicin (Adriamycin), dexamethasone (Decadron) | Burkitt's lymphoma |
| ICE [12]' | Ifosfamide, carboplatin, etopiside | Relapsed or primary refractory non-Hodgkin lymphoma |
| ICE-R | ICE + rituximab | Relapsed or primary refractory non-Hodgkin lymphoma |
| IFL [13] | Irinotecan, bolus fluorouracil and leucovorin | Metastatic colorectal cancer |
| m-BACOD | Methotrexate, bleomycin, doxorubicin (Adriamycin), cyclophosphamide, vincristine (Oncovin), dexamethasone (Decadron) | Non-Hodgkin lymphoma |
| MACOP-B [14] | Methotrexate, leucovorin, doxorubicin (Adriamycin), cyclophosphamide, vincristine (Oncovin), prednisone, bleomycin | Non-Hodgkin lymphoma |
| Mini-BEAM [15] | Carmustine (BCNU), etopiside, cytarabine (Ara-C), melphalan | Hodgkin's lymphoma (Salvage therapy, pre-transplant) |
| MOPP | Mechlorethamine, vincristine (oncovin), procarbazine, prednisone | Hodgkin's lymphoma |
| MVAC [16] | Methotrexate, vinblastine, doxorubicin, cisplatin | Bladder cancer |
| NABTT [17] | Methotrexate, calcium leucovorin; methotrexate, calcium leucovorin; methotrexate, calcium leucovorin | Primary CNS lymphoma |
| PCV [18] | Procarbazine, lomustine (CCNU), vincristine | Brain tumors |
| ProMACE-MOPP | Methotrexate, doxorubicin (Adriamycin), cyclophosphamide, etoposide + MOPP | Non-Hodgkin lymphoma |
| ProMACE-CytaBOM | Prednisone, doxorubicin (adriamycin), cyclophosphamide, etoposide, cytarabine, bleomycin, vincristine (Oncovin), methotrexate, leucovorin | Non-Hodgkin lymphoma |
| R-FCM | Rituximab, fludarabine, cyclophosphamide, mitoxantrone | B cell non-Hodgkin lymphoma |
| RTOG 93-10 [19] | Methotrexate, Leucovorin, vincristine, procarbazine, methotrexate, Leucovorin | Primary CNS lymphoma |
| Stanford V [20] | Doxorubicin (Adriamycin), mechlorethamine, bleomycin, vinblastine, vincristine (Oncovin), etoposide (VP-16), prednisone | Hodgkin's lymphoma |
| TAC [21] | Docetaxel, doxorubicin, cyclophosphamide | Metastatic breast cancer |
| TAP [22] | Paclitaxel, doxorubicin, cisplatin | Endometrial cancer |
| Thal/Dex | Thalidomide, dexamethasone | Multiple myeloma |
| Treanda + Rituxan | Bendamustine, Rituximab | Indolent and mantle cell lymphomas |
| VAD | Vincristine, Adriamycin (doxorubicin), dexamethasone | Multiple myeloma |
| VCAP-AMP-VECP [23] | Vincristine, cyclophosphamide, doxorubicin, and prednisone (VCAP)--doxorubicin, ranimustine, and prednisone (AMP)-- vindesine, etoposide, carboplatin, and prednisone (VECP) | Adult T-cell leukemia-lymphoma (ATLL) |
| VeIP [24] | Vinblastine, ifosfamide, cisplatin | Testicular cancer |
| VIP [25] | Etopiside, ifosfamide, cisplatin | Testicular cancer |
- ↑ Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C (1975). "Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP". Cancer. 36 (1): 252–9. PMID 54209. Unknown parameter
|month=ignored (help) - ↑ Schwartz CL, Constine LS, Villaluna D; et al. (2009). "A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425". Blood. 114 (10): 2051–9. doi:10.1182/blood-2008-10-184143. PMID 19584400. Unknown parameter
|month=ignored (help) - ↑ Berruti A, Borasio P, Gerbino A; et al. (1999). "Primary chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide in locally advanced thymomas: a single institution experience". Br. J. Cancer. 81 (5): 841–5. doi:10.1038/sj.bjc.6690773. PMC 2374302. PMID 10555755. Unknown parameter
|month=ignored (help) - ↑ Diehl V, Franklin J, Hasenclever D; et al. (1998). "BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group". J. Clin. Oncol. 16 (12): 3810–21. PMID 9850026. Unknown parameter
|month=ignored (help) - ↑ Mead GM, Sydes MR, Walewski J; et al. (2002). "An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study". Ann. Oncol. 13 (8): 1264–74. PMID 12181251. Unknown parameter
|month=ignored (help) - ↑ Wilson WH, Grossbard ML, Pittaluga S; et al. (2002). "Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy". Blood. 99 (8): 2685–93. PMID 11929754. Unknown parameter
|month=ignored (help) - ↑ Velasquez WS, Cabanillas F, Salvador P; et al. (1988). "Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP)". Blood. 71 (1): 117–22. PMID 3334893. Unknown parameter
|month=ignored (help) - ↑ Lignon J, Sibon D, Madelaine I; et al. (2010). "Rituximab, Dexamethasone, Cytarabine, and Oxaliplatin (R-DHAX) Is an Effective and Safe Salvage Regimen in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma". Clin Lymphoma Myeloma Leuk. 10 (4): 262–9. doi:10.3816/CLML.2010.n.055. PMID 20709662. Unknown parameter
|month=ignored (help) - ↑ McLaughlin P, Hagemeister FB, Romaguera JE; et al. (1996). "Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma". J. Clin. Oncol. 14 (4): 1262–8. PMID 8648382. Unknown parameter
|month=ignored (help) - ↑ Douillard JY, Cunningham D, Roth AD; et al. (2000). "Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial". Lancet. 355 (9209): 1041–7. PMID 10744089. Unknown parameter
|month=ignored (help) - ↑ Thomas DA, Cortes J, O'Brien S; et al. (1999). "Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia". J. Clin. Oncol. 17 (8): 2461–70. PMID 10561310. Unknown parameter
|month=ignored (help) - ↑ Moskowitz CH, Bertino JR, Glassman JR; et al. (1999). "Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma". J. Clin. Oncol. 17 (12): 3776–85. PMID 10577849. Unknown parameter
|month=ignored (help) - ↑ Saltz LB, Cox JV, Blanke C; et al. (2000). "Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group". N. Engl. J. Med. 343 (13): 905–14. PMID 11006366. Unknown parameter
|month=ignored (help) - ↑ Klimo P, Connors JM (1985). "MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma". Ann. Intern. Med. 102 (5): 596–602. PMID 2580468. Unknown parameter
|month=ignored (help) - ↑ Colwill R, Crump M, Couture F; et al. (1995). "Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation". J. Clin. Oncol. 13 (2): 396–402. PMID 7844600. Unknown parameter
|month=ignored (help) - ↑ von der Maase H, Hansen SW, Roberts JT; et al. (2000). "Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study". J. Clin. Oncol. 18 (17): 3068–77. Unknown parameter
|month=ignored (help) - ↑ Herrlinger U, Schabet M, Brugger W; et al. (2002). "German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma". Ann. Neurol. 51 (2): 247–52. PMID 11835382. Unknown parameter
|month=ignored (help) - ↑ Levin VA, Edwards MS, Wright DC; et al. (1980). "Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors". Cancer Treat Rep. 64 (2–3): 237–44. PMID 7407756.
- ↑ DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ (2002). "Combination chemotherapy and radiotherapy for primary central nervous system". J. Clin. Oncol. 20 (24): 4643–8. PMID 12488408. Text " lymphoma: Radiation Therapy Oncology Group Study 93-10 " ignored (help); Unknown parameter
|month=ignored (help) - ↑ Bartlett NL, Rosenberg SA, Hoppe RT, Hancock SL, Horning SJ (1995). "Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report". J. Clin. Oncol. 13 (5): 1080–8. PMID 7537796. Unknown parameter
|month=ignored (help) - ↑ Nabholtz JM, Mackey JR, Smylie M; et al. (2001). "Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer". J. Clin. Oncol. 19 (2): 314–21. PMID 11208821. Unknown parameter
|month=ignored (help) - ↑ Fleming GF, Brunetto VL, Cella D; et al. (2004). "Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study". J. Clin. Oncol. 22 (11): 2159–66. doi:10.1200/JCO.2004.07.184. PMID 15169803. Unknown parameter
|month=ignored (help) - ↑ Tsukasaki K, Utsunomiya A, Fukuda H; et al. (2007). "VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801". J. Clin. Oncol. 25 (34): 5458–64. doi:10.1200/JCO.2007.11.9958. PMID 17968021. Unknown parameter
|month=ignored (help) - ↑ Loehrer PJ, Gonin R, Nichols CR, Weathers T, Einhorn LH (1998). "Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor". J. Clin. Oncol. 16 (7): 2500–4. PMID 9667270. Unknown parameter
|month=ignored (help) - ↑ Nichols CR, Catalano PJ, Crawford ED, Vogelzang NJ, Einhorn LH, Loehrer PJ (1998). "Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study". J. Clin. Oncol. 16 (4): 1287–93. PMID 9552027. Unknown parameter
|month=ignored (help)